Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective

N Kakouros, JJ Rade, A Kourliouros… - International journal of …, 2011 - Wiley Online Library
Patients with diabetes mellitus have an increased prevalence of vascular disease.
Pathologic thrombosis associated with atherosclerotic plaque rupture is a major cause of …

[HTML][HTML] The main determinants of diabetes mellitus vascular complications: endothelial dysfunction and platelet hyperaggregation

A Carrizzo, C Izzo, M Oliveti, A Alfano… - International journal of …, 2018 - mdpi.com
Diabetes mellitus is a common disease that affects 3–5% of the general population in Italy.
In some countries of northern Europe or in North America, it can even affect 6–8% of the …

[HTML][HTML] Impact of cigarette smoking and smoking cessation on life expectancy among people with HIV: a US-based modeling study

KP Reddy, RA Parker, E Losina… - The Journal of …, 2016 - academic.oup.com
Background In the United States,> 40% of people infected with human immunodeficiency
virus (HIV) smoke cigarettes. Methods We used a computer simulation of HIV disease and …

Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

M Samuel, JC Tardif, P Khairy, F Roubille… - … Journal-Quality of …, 2021 - academic.oup.com
Aims In the randomized, placebo-controlled Colchicine Cardiovascular Outcomes Trial
(COLCOT) of 4745 patients enrolled within 30 days after myocardial infarction (MI), low-dose …

Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to …

EM Mahoney, K Wang, SV Arnold, I Proskorovsky… - Circulation, 2010 - Am Heart Assoc
Background—In patients with acute coronary syndromes and planned percutaneous
coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by …

Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project

D De Smedt, K Kotseva, D De Bacquer… - European heart …, 2012 - academic.oup.com
Abstract Aims The EUROASPIRE III survey indicated that the guidelines on cardiovascular
disease prevention are poorly implemented in patients with established coronary heart …

Do value thresholds for oncology drugs differ from nononcology drugs?

YHJ Bae, CD Mullins - Journal of Managed Care Pharmacy, 2014 - jmcp.org
BACKGROUND: In the past decade, many oncologic drugs have been approved that extend
life and/or improve patients' quality of life. However, new cancer drugs are often associated …

Cumulative adherence to secondary prevention guidelines and mortality after acute myocardial infarction

MD Solomon, TK Leong, E Levin, JS Rana… - Journal of the …, 2020 - Am Heart Assoc
Background The survival benefit associated with cumulative adherence to multiple clinical
and lifestyle‐related guideline recommendations for secondary prevention after acute …

Cost-effectiveness of medical, endovascular and surgical management of peripheral vascular disease

Z Fanari, WS Weintraub - Cardiovascular Revascularization Medicine, 2015 - Elsevier
Peripheral arterial disease (PAD) is responsible for 20% of all US hospital admissions.
Management of PAD has evolved over time to include many medical and transcatheter …

Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: results from the PEGASUS-TIMI 54 trial

EA Magnuson, H Li, K Wang, K Vilain, A Shafiq… - Journal of the American …, 2017 - jacc.org
Background: In patients with a myocardial infarction (MI) 1 to 3 years earlier, treatment with
ticagrelor+ low-dose aspirin (ASA) reduces the risk of cardiovascular (CV) death, MI, or …